Grifols (GRF) Q3 2024 earnings summary

Executive summary

• Achieved strong Q3 2024 results with revenue up 12.4% year-over-year at constant currency, led by Biopharma growth and contributions from all business units and core markets.

• Adjusted EBITDA for Q3 reached EUR 462 million (25.8% margin), up 26.7% year-over-year; year-to-date Adjusted EBITDA at EUR 1,253 million (23.9% margin), up 25%.

• Free cash flow improved to EUR 127 million in Q3, reflecting better working capital management and a significant turnaround from earlier quarters.

• Leverage ratio reduced to 5.1x from 6.8x in Q1, with all SRAAS sale proceeds (EUR 1.6 billion) allocated to debt reduction.

• Management transition completed with new CFO; ongoing focus on governance, performance culture, and leadership strengthening.

Financial highlights

• Q3 2024 revenue: EUR 1,793 million (+12.4% YoY constant currency); YTD revenue: EUR 5,237 million (+9.1%).

• Adjusted EBITDA Q3: EUR 462 million (25.8% margin); YTD adjusted EBITDA: EUR 1,253 million (23.9% margin); reported EBITDA Q3: EUR 425 million (23.7% margin).

• Free cash flow Q3: EUR 127 million; liquidity at end of Q3: EUR 704 million.

• Net profit attributable to the group in Q3 2024 was EUR 51.7 million; YTD group profit at EUR 88 million, with net income excluding one-offs at EUR 264 million for the first nine months.

• Net financial debt as of September 30, 2024, was EUR 8,128 million; liquidity position at EUR 704 million.

Outlook and guidance

• Full-year 2024 guidance reiterated, with confidence in meeting revenue and Adjusted EBITDA targets; Q4 expected to be demanding but feasible.

• Free cash flow breakeven targeted for year-end; 2025 guidance to be provided at next earnings call.

• Continued focus on deleveraging, cost control, operational improvements, and R&D pipeline acceleration.